EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.

View source ↗

Summary

EMA authorised Junod, a denosumab product from Gedeon Richter, for osteoporosis and postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Junod (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Gedeon Richter Plc.. Decision date: 22/12/2025